Market News AIOpen the app

Keros Therapeutics will buy back up to $5 million in its own stock after getting $20 million from Takeda.

PayoutRead the original at SEC EDGAR
Good for KROS

Keros received a $20 million Takeda payment and approved spending up to $5 million on shares. That could use some cash, but Keros expects enough to cover planned costs into 2029 after the purchases.

KROS · Keros Therapeutics, Inc.

AI read · Good for KROS

The AI's read

The Takeda payment adds cash, and Keros says it can cover planned costs into 2029 after the share purchases. The company may spend up to $5 million, but it does not have to.

Get alerts for KROS

Follow Keros Therapeutics, Inc. (KROS) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for KROS
Free on the App Store and Google Play, or on the web.